External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia

Cancer

Volumn 119, Issue 6, 2013, Pages 1177-1185

  Molica, Stefano ^a   Giannarelli, Diana ^b   Gentile, Massimo ^c   Cutrona, Giovanna ^d   Di Renzo, Nicola ^e   Di Raimondo, Francesco ^f   Neri, Antonino ^g   Federico, Massimo ^h   Ferrrarini, Manlio ^d   Morabito, Fortunato ^c  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Unit of Geriatrics   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e Lecce Local Health Service   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

early chronic lymphocytic leukemia; nomogram validation; prognostic index; time to first treatment

Indexed keywords

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PREDICTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

ADULT; AGED; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NOMOGRAMS; PROGNOSIS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874675941     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27900     Document Type: Article

References (29)

1. Caligaris-Cappio F, Ghia P,. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol. 2008; 26: 4497-4503.
2. Wierda WG, O'Brien S, Wang X, et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009; 27: 1637-1643.
3. Wierda WG, O'Brien S, Wang X, et al. Multivariate model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011; 29: 4088-4095.
4. Iasonos A, Schrag D, Raj GV, Panageas KS,. How to Build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008; 26: 1364-1370.
5. Molica S, Mauro FR, Callea V, et al. The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica. 2010; 95: 464-469.
6. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990-4997.
7. Cutrona G, Colombo M, Matis S, et al. Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. Haematologica. 2008; 93: 413-422.
8. Morabito F, De Filippi R, Laurenti L, et al. The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood. 2011; 118: 6353-6361.
9. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998; 102: 1515-1525.
10. Fabris S, Mosca L, Todoerti K, et al. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2008; 47: 781-793.
11. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111: 5446-5456.
12. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361-387.
13. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 1910-1916.
14. Molica S, Mauro FR, Callea V, et al. A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2005; 46: 553-560.
15. Del Giudice I, Morilla A, Osuji N, et al. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer. 2005; 104: 2124-2132.
16. Krober A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol. 2006; 24: 969-975.
17. Morilla A, Gonzalez de Castro D, Del Giudice I, et al. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. Leuk Lymphoma. 2008; 49: 2108-2115.
18. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008; 112: 1923-1930.
19. Morabito F, Cutrona G, Gentile M, et al. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Br J Haematol. 2009; 146: 44-53.
20. Letestu R, Levy V, Eclache V, et al. Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood. 2010; 116: 4588-4590.
21. Pepper C, Majid A, Lin TT, et al. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol. 2012; 156: 499-507.
22. Molica S, Mauro FR, Giannarelli D, et al. Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA Chronic Lymphoproliferative Diseases Working Group. Haematologica. 2011; 96: 277-283.
23. Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007; 109: 4679-4685.
24. Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 2009; 115: 363-372.
25. Shanafelt TD, Rabe KG, Kay NE, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010; 116: 4777-4787.
26. Wiestner A,. Emerging role of kinase targeted strategies in chronic lymphocytic leukemia [published online ahead of print August 8, 2012]. Blood. 2012.
27. Bochner BH, Kattan MW, Vora KC,. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006; 24: 3967-3972.
28. Alran S, De Rycke Y, Fourchotte V, et al. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol. 2007; 14: 2195-2201.
29. Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007; 25: 1316-1322.